Fibroblast Growth Factor 21 and Obesity Related Cardio-Metabolic Dysfunction in Rats
/ 0
- Details
- Category: Vol. 85, June 2017
- Hits: 590
Fibroblast Growth Factor 21 and Obesity Related Cardio-Metabolic Dysfunction in Rats, AHMED A. ABD AL-FATTAH and YASSER M. ABD EL-RAOUF
Abstract
Background: Fibroblast Growth Factor 21 (FGF21) is considered a typical member of the FGF family that functions as an endocrine factor and a metabolic regulator. In obesity state, elevation of FGF21 helps improvement of hyperglycemia and hyperlipidemia and increases insulin sensitivity. These beneficial effects may improve obesity induced cardiac com-plications.
Methods: Thirty male Wister Albino rats were fed on either a normal diet (n=10) or a High-Fat Diet (HFD; n=20) for 12 weeks. Then, rats in the HFD group were divided into two subgroups (n=10 per subgroup) and received either the vehicle (HFV) or human FGF21 (0. 1mgKg–1 day–1; HFF) intraperitoneally administered for 28 days. The metabolic parameters, inflammation, malondialdehyde (MDA), MAP, left ventricular function, Heart Rate Variability (HRV), plasma FGF21, % of fractional shortening (%FS) and cardiac mito-chondrial ROS production were assessed.
Results: HFV rats had increased dyslipidemia, insulin resistance, plasma FGF21 levels, TNF-a, serum and cardiac MDA and decreased adiponectin, HRV, and impaired LV and mitochondrial function. However FGF21 restored metabolic parameters, decreased TNF-a and MDA, increased serum adiponectin, and improved HRV, cardiac mitochondrial and LV function in HFF rats.
Conclusion: FGF21 improved obesity related hazards especially the metabolic and cardiac hazards.